Capstone final draft
Please see the attachment for the instructions
Please see the attachment for the instructions
After studying Module 3: Lecture Materials & Resources, discuss the following:
How has COVID-19 affected your personal beliefs/values in your clinical practice? Include an example.
The Assignment (2-3 pages):
Personal Leadership Philosophies
Develop and submit a personal leadership philosophy that reflects what you think are characteristics of a good leader. Use the scholarly resources on leadership you selected to support your philosophy statement. Your personal leadership philosophy should include the following:
[removed]
Develop a Focused SOAP Note, including your differential diagnosis and critical-thinking process to formulate a primary diagnosis. Incorporate the following into your responses in the template:
all i need is paraphrazing this work sample.
Advanced Psychopharmacology and Health Promotion
Unit 9 peer response. ADHD Medications. 800W. APA. 4 references due 10-30-23.
Instructions:
Please read and respond to at least two of your peers' initial postings. You may want to consider the following questions in your responses to your peers:
· Compare and contrast your initial posting with those of your peers.
· How are they similar or how are they different?
· What information can you add that would help support the responses of your peers?
· Ask your peers a question for clarification about their post.
· What most interests you about their responses?
Please be sure to validate your opinions and ideas with citations and references in APA format.
Unit 9 – ADHD Medications
1.
What screening tools can be used to affirm your initial diagnosis that Mr. Deliver meets the criteria for ADHD?
One commonly used screening tool is the Adult ADHD Self-Report Scale (ASRS). The ASRS consists of a series of questions that evaluate both inattentive and hyperactive-impulsive symptoms (Anbarasan et al., 2020). Another useful screening tool is the Conners' Adult ADHD Rating Scales (CAARS), which assesses various domains affected by ADHD, such as attention problems, hyperactivity/impulsivity, and executive functioning (Smyth et al., 2019).
2.
Further assessment determines that Mr. Deliver does meet the criteria for ADHD, inattentive type. What is the current recommendation for pharmacological treatment for Mr. Deliver?
Once it is confirmed through further assessment that Mr. Deliver meets the criteria for ADHD, inattentive type, the current recommendation for pharmacological treatment would typically involve stimulant medications such as methylphenidate or amphetamine derivatives. These medications have consistently shown efficacy in improving attention, reducing impulsivity, and enhancing executive functions in adults with ADHD (Farhat et al., 2022). Non-stimulant options like atomoxetine or viloxazine (norepinephrine modulator) may also be considered if there are contraindications or intolerance to stimulants (Mechler et al., 2022). However, considering Mr. Deliver's concerns about stigma and psychotropic medications' risks, it may be worth discussing non-pharmacological interventions as well. Cognitive-behavioral therapy (CBT) has demonstrated efficacy in managing symptoms of adult ADHD. CBT can help Mr. Deliver develop strategies to improve organization skills, time management, and enhance his ability to focus on tasks (Young et al., 2020).
3.
Assume that instead of Mr. Deliver being 36 years old, Thomas is a 13-year-old male that also meets the diagnostic criteria for ADHD, hyperactive type (Thomas is not on any medications at this age). How will your pharmacological treatment change?
In the case of Thomas, a 13-year-old boy diagnosed with ADHD hyperactive type who is not currently taking any medications, the most probable treatment approach would involve the use of stimulant medications. According to the American Academy of Pediatrics (AAP), stimulant medications like methylphenidate are recommended as first-line treatment options for children and adolescents with ADHD, as they have been shown effective in reducing symptoms and improving functioning (Shrestha et al., 2020). However it is important to monitor growth and potential side effects in pediatric patients (Vertessen et al., 2023).
References
Anbarasan, D., Kitchin, M., & Adler, L. A. (2020). Screening for adult adhd.
Current Psychiatry Reports,
22(12).
https://doi.org/10.1007/s11920-020-01194-9Links to an external site.
Farhat, L. C., Flores, J. M., Behling, E., Avila-Quintero, V. J., Lombroso, A., Cortese, S., Polanczyk, G. V., & Bloch, M. H. (2022). The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: A meta-analysis.
Molecular Psychiatry,
27(3), 1562–1572.
https://doi.org/10.1038/s41380-021-01391-9Links to an external site.
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for adhd in children and adolescents.
Pharmacology & Therapeutics,
230, 107940.
https://doi.org/10.1016/j.pharmthera.2021.107940Links to an external site.
Shrestha, M., Lautenschleger, J., & Soares, N. (2020). Non-pharmacologic management of attention-deficit/hyperactivity disorder in children and adolescents: A review.
Translational Pediatrics,
9(S1), S114–S124.
https://doi.org/10.21037/tp.2019.10.01Links to an external site.
Smyth, A. C., & Meier, S. T. (2016). Evaluating the psychometric properties of the conners adult adhd rating scales.
Journal of Attention Disorders,
23(10), 1111–1118.
https://doi.org/10.1177/1087054715624230Links to an external site.
Vertessen, K., Luman, M., Swanson, J. M., Bottelier, M., Stoffelsen, R., Bet, P., Wisse, A., Twisk, J. R., & Oosterlaan, J. (2023). Methylphenidate dose–response in children with adhd: Evidence from a double-blind, randomized placebo-controlled titration trial.
European Child & Adolescent Psychiatry.
https://doi.org/10.1007/s00787-023-02176-xLinks to an external site.
Young, Z., Moghaddam, N., & Tickle, A. (2016). The efficacy of cognitive behavioral therapy for adults with adhd: A systematic review and meta-analysis of randomized controlled trials.
Journal of Attention Disorders,
24(6), 875–888.
https://doi.org/10.1177/1087054716664413Links to an external site.
Unit 9: Initial Discussion ADHD Medications
What screening tools can be used to affirm your initial diagnosis that Mr. Deliver meets the criteria for ADHD?
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common neuropsychiatric disorder of childhood, with impairing symptoms persisting into adulthood in approximately 70% of cases. Several screening tools are available to help providers identify and diagnose ADHD. The World Health Organization (WHO) Adult ADHD Self-Report Scale Part A is the most commonly used screening tool for ADHD cases in adults. The tool is available in national and international ADHD guidelines. The screening tool contains six questions that cover inattentive and hyperactive-impulsive symptoms. It also includes a threshold of four or more, which is used for probable ADHD. The score is calculated according to the number of questions that meet the criteria: sometimes endorsing/often/very often for questions 1–3 and endorsing usually/very often for questions 4–6. However, this screening, even if the patient is positive, may not have an active diagnosis of ADHD; further evaluation is required to ensure symptoms are related to ADHD diagnosis (Chamberlain et al., 2021).
Further assessment determines that Mr. Deliver does meet the criteria for ADHD, inattentive type. What is the current recommendation for pharmacological treatment for Mr. Deliver?
According to his age and diagnosis, the current recommendation for this patient will be amphetamine 12.5 mg daily. Recommend that the patient start CBT and encourage exercise. A study showed that ADHD drugs are more effective and tolerated by children and adolescents than adults; the reason for this discrepancy is unknown. Amphetamines, methylphenidate, atomoxetine, and modafinil cause weight loss in children, adolescents, and adults. Amphetamines and atomoxetine increased blood pressure in children and adolescents, and methylphenidate increased blood pressure in adults. Methylphenidate showed better symptom control with the most minor side effects for children and adolescents, and amphetamines produced the best results for adults (Gupta, 2018).
Reference:
Chamberlain, S. R., Cortese, S., & Grant, J. E. (2021). Screening for adult ADHD using brief rating tools: What can we conclude from a positive screen? Some caveats.
Comprehensive Psychiatry,
106, 152224. https://doi.org/10.1016/j.comppsych.2021.152224
Gupta, S. (2018). Best First-Line ADHD Medications for Children, Adults: Study Results.
Attitude. https://www.additudemag.com/adhd-drugs-methylphenidate-vs-amphetamine-treatment/
Mayo Clinic. (2023). Amphetamine (Oral Route).
https://www.mayoclinic.org/drugs-supplements/amphetamine-oral-route/proper-use/drg-20150941Links to an external site.
Case: 8 year old overweight male foster child with normal weight foster parents and overweight biological parents.
include the following:
1.Introduction
2.An explanation of the health issues and risks that are relevant to the child you were assigned.
3.Describe additional information for assessment you would need in order to further assess his or her weight-related health.
4.Identify and describe any risks and consider what further information you would need to gain a full understanding of the child’s health. Think about how you could gather this information in a sensitive fashion. Identifying Risks and Gathering Sensitive Information
5.Taking into account the parents’ and caregivers’ potential sensitivities, list at least three specific questions you would ask about the child to gather more information. Specific Questions for Information Gathering
6.Provide at least two strategies you could employ to encourage the parents or caregivers to be proactive about their child’s health and weight.
7.Conclusion
Module 02 Content
To prepare for the live classroom session and your written submission, use your chapter readings and course materials.
The focus for this live classroom is on Dietary Reference Intakes (DRI). You can review information about DRI at
https://www.nal.usda.gov/fnic/dietary-reference-intakes
Complete the Interactive DRI on yourself. Go to https://www.nal.usda.gov/fnic/dri-calculator/
Be prepared to answer the following questions:
What are the three components of the DRI?
Describe how RDA, AI, and UL influence health?
After reviewing your results on the Interactive DRI, how well are you meeting the RDAs suggested?
What two changes can you make to improve?
After the live classroom discussion, submit written answers to the above questions.
Focus on promoting student engagement and active learning to promote interpersonal and academic integrity.
From a student perspective, faculty are central to the learning experience. Many of our students spend the greatest amount of time in class interacting with faculty. As such, faculty have the opportunity to cultivate relationships with students and are often in the best position to become aware of violations of academic integrity. Examine how nursing faculty can collectively cultivate an environment that positively contributes to active learning and proactively prevents/responds to student misconduct and cheating? Consider legal and ethical implications in your response.
Sources: You may use your text books and other reading material, but you must also include at least two additional articles from peer reviewed nursing journals.
See Attached
Nursinghomeworkdesk.com is a unique service that provides guidance with different types of content. Please rest assured that the service is absolutely legal and doesn’t violate any regulations.
Home
Writing Services
About Us
Pricing
Email:
[email protected]
Phone:
+1 (231)-518-0303